Published 2 years ago

Djokovic buys 80% in Danish biotech Develi'nin COVID-19 treatment

Summary by Ground News

Tennis champion Novak Djokovic has an 80% stake of Danish biotech firm QuantBioRes. The company is aiming to develop a medical treatment to counter COVID-19. CEO Ivan Loncarevic, who described himself as an entrepreneur, said the investment was made in June 2020.

0 Articles

All

Left

Center

Right

Times of India

Djokovic holds 80% of Danish biotech developing COVID treatment: CEO

Off the field News: Tennis champion Novak Djokovic has an 80% stake of Danish biotech firm QuantBioRes, which is aiming to develop a medical treatment to counter COVID-19

2 years ago·India

Read Full Article

BBC News

Novak Djokovic is the majority shareholder of a biotech company seeking a treatment for covid that does not require a vaccine - BBC News World

The number one in world tennis owns 80% of the company, which is looking for a cure for covid-19.

2 years ago·United Kingdom

Read Full Article

The Guardian

Djokovic has 80% stake in biotech firm developing Covid drug

QuantBioRes is working on a treatment not a vaccine, but CEO says tennis star is ‘not anti-vax’

2 years ago·London, United Kingdom

Read Full Article

CTV News

Novak Djokovic holds 80 per cent of Danish biotech developing COVID-19 treatment: CEO

Tennis champion Novak Djokovic has an 80 per cent stake of Danish biotech firm QuantBioRes, which is aiming to develop a medical treatment to counter COVID-19, the company's chief executive told Reuters on Wednesday.

2 years ago·Canada

Read Full Article

The Independent

Novak Djokovic owns biotechnology company developing treatment for Covid

The world number one made the 80 per cent purchase of QuantBioRes in June 2020

2 years ago·London, United Kingdom

Read Full Article

Reuters

Djokovic buys 80% in Danish biotech developing COVID-19 treatment

COPENHAGEN - Tennis player Novak Djokovic has purchased 80% of Danish biotech firm QuantBioRes, aiming to develop a medical treatment against COVID-19, the company's chief executive told Reuters. (Reporting by Nikolaj Skydsgaard; Editing by Alison Williams)

2 years ago·United Kingdom

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.